朱沙：教授，博士生导师，研究方向：肿瘤免疫与靶向治疗。曾于华盛顿大学（University of Washington）和弗雷德癌症研究中心（Fred Hutchinson Cancer Research Center)访学，进行肿瘤免疫相关研究工作。主持并完成的项目包括国家自然科学基金项目、留学归国人员择优资助项目、博士后基金资助项目、河南省自然科学基金面上项目，河南省国际合作项目、河南省科技攻关项目、河南省教育厅高等学校重点科研项目等；承担并完成的教改项目包括中华医学会、河南省卫健委等教改项目多项；获得河南省人民政府颁发科技进步二等奖1项、科技进步三等奖2项；获得河南省科协自然科学二等奖1项；获得河南省科技厅以及教育厅优秀论文一等奖4项，获得河南省教育厅优秀成果一等奖3项；发表SCI、EI等研究论文40余篇，获得授权发明专利、新型专利等8项；参编中英文著作多部。

Emial：shaz06@163.com

代表性研究论文：

[1] Shen, Danpeng; Xie, Fan; Chen, Weikang; Lv, Shixian; Chen, Shengxian; Qin, Xi; Zhu, Sha*. Preclinical Efficacy Assessment of Umbilical Cord Mesenchymal Stem Cell Therapy for Acute Liver Failure. Iran J Basic Med Sci‌. 2025 Oct. 1-9.

[2] Zhang, He; Qin, Guohui; Yu, Hui; Han, Xu; Zhu Sha*. Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer. Cancer Immunol Immunother. 2021 Jun;70(6):1649-1665.doi: 10.1007/s00262-020-02807-1.

[3] Meng, Fanjing; Han, Xu; Min, Zhixue; He, Xuehui; Zhu, Sha*. Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer. Aging (Albany NY). 2021 Jul 6;13(13):17442-17461. doi: 10.18632/aging.203234.

[4] Zhang, He; Lin, Ying; Wang, Jin; Lv Renguang; Meng, Fanjing; Zhu, Sha*. Synergistic activity of insulin combined with glucose on Toxoplasma gondii proliferation in Vero cells. Chin Med J (Engl). 2021 May 4. doi: 10.1097/CM9.0000000000001516.

[5] Zhu, Sha*; Han, Xu; Qiao, Xianli; Chen, Shengxian. The immune landscape and prognostic immune key genes potentially involved in modulating synaptic functions in prostate cancer. Frontiers in Oncology. 2020 Aug 14;10:1330. doi: 10.3389/fonc.2020.01330.

[6] Zhu Sha*; Min, Zhixue; Qiao, Xianli*; Chen, Shengxian; Yang, Jian; Zhang, Xiao; Liu, Xigang; Ran, Weijie; Lv Renguang; Lin, Ying; Wang, Jin. Expression profile-based screening for critical genes reveals S100A4, ACKR3 and CDH1 in docetaxel-resistant prostate cancer cells. Aging (Albany NY). 2019 Dec 29;11(24):12754-12772.

[7] Li S, Li R, Ma Y, Zhang C, Huang T, Zhu S*. Transcriptome analysis of differentially expressed genes and pathways associated with mitoxantrone treatment prostate cancer. J Cell Mol Med. 2019 Mar;23(3):1987-2000. doi: 10.1111/jcmm.14100.

[8] Zhu S*, Oremo JA, Li SQ, Zhen MH, Tang Y, Du Y. Synergistic antitumor activities of Docetaxel and Octreotide associated with apoptotic- upregulation in castration-resistant prostate cancer. Plos One. 2014 Mar 14;9(3):e91817. doi: 10.1371/journal.

[9] Zhu S*, Li M, Zhen MH, Oremo JA, Sun SH. Silencing of aldo-keto reductase 1C3 by siRNA increases chemosensitivity of prostate cancer cells. Journal of Chemical and Pharmaceutical Research. 2013 5(12):404-408.

[10] Zhu S*; Gong GM, Oremo JA, Zhen MH, Huang T, Tang Y, Feng GQ. Microarray and pathway analysis of differential gene expression between two kinds of prostate cancer cell lines sensitive and insensitive to docetaxel. Information Technology Journal, 2013 12(24)8281-8286.